These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25261297)

  • 1. Anti- or pro-proliferation—conditional options for TGF-α and cetuximab in head and neck squamous cell carcinoma.
    Ekblad L; Welinder C; Kjellén E; Brun E; Wennerberg J
    Oral Oncol; 2015 Jan; 51(1):46-52. PubMed ID: 25261297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin.
    Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U
    Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.
    Oshima G; Wennerberg J; Yamatodani T; Kjellén E; Mineta H; Johnsson A; Ekblad L
    J Cancer Res Clin Oncol; 2012 Mar; 138(3):491-9. PubMed ID: 22193422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined molecular targeted drug therapy for EGFR and HER-2 in head and neck squamous cell carcinoma cell lines.
    Kondo N; Tsukuda M; Sakakibara A; Takahashi H; Hyakusoku H; Komatsu M; Niho T; Nakazaki K; Toth G
    Int J Oncol; 2012 Jun; 40(6):1805-12. PubMed ID: 22344385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
    Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
    J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
    Grandis JR; Chakraborty A; Zeng Q; Melhem MF; Tweardy DJ
    J Cell Biochem; 1998 Apr; 69(1):55-62. PubMed ID: 9513046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
    Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
    PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.
    Hoffmann T; Hafner D; Ballo H; Haas I; Bier H
    Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
    Rubin Grandis J; Chakraborty A; Melhem MF; Zeng Q; Tweardy DJ
    Oncogene; 1997 Jul; 15(4):409-16. PubMed ID: 9242377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model.
    Gustafsson H; Kale A; Dasu A; Lund A; Edqvist PH; Roberg K
    Cell Biochem Biophys; 2017 Dec; 75(3-4):299-309. PubMed ID: 28756482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.
    Ansell A; Jedlinski A; Johansson AC; Roberg K
    J Oral Pathol Med; 2016 Jan; 45(1):9-16. PubMed ID: 25677871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting EGFR-positive cancer cells with cetuximab-ZZ-PE38: Results of in vitro and in vivo studies.
    Barnea I; Ben-Yosef R; Karaush V; Benhar I; Vexler A
    Head Neck; 2013 Aug; 35(8):1171-7. PubMed ID: 22965815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of bortezomib and cetuximab in EGF-stimulated HNSCC.
    Wagenblast J; Baghi M; Arnoldner C; Bisdas S; Gstöttner W; Ackermann H; May A; Knecht R; Hambek M
    Anticancer Res; 2008; 28(4B):2239-43. PubMed ID: 18751401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells.
    Zhang Q; Thomas SM; Xi S; Smithgall TE; Siegfried JM; Kamens J; Gooding WE; Grandis JR
    Cancer Res; 2004 Sep; 64(17):6166-73. PubMed ID: 15342401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells.
    Lango M; Wentzel AL; Song JI; Xi S; Johnson DE; Lamph WW; Miller L; Grandis JR
    Clin Cancer Res; 2003 Sep; 9(11):4205-13. PubMed ID: 14519647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma.
    Rubin Grandis J; Tweardy DJ; Melhem MF
    Clin Cancer Res; 1998 Jan; 4(1):13-20. PubMed ID: 9516947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
    Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
    J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.